{
    "root": "1185399f-47c1-4e12-bee5-20198212af65",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Livtencity",
    "value": "20250304",
    "ingredients": [
        {
            "name": "MARIBAVIR",
            "code": "PTB4X93HE1"
        },
        {
            "name": "Microcrystalline cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D"
        },
        {
            "name": "Magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "Titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FD&C Blue NO. 1",
            "code": "H3R47K3TBD"
        }
    ],
    "indications": "LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14)].",
    "contraindications": "400 mg (two 200 mg tablets) orally twice daily with or without food. ( 2.1 , 8.4 )",
    "warningsAndPrecautions": "Tablet: 200 mg, blue, oval shaped convex tablet debossed with \"SHP\" on one side and \"620\" on the other side. They are supplied as follows:\n                  Bottles of 28 tablets with child-resistant caps (NDC 64764-800-28)\n                  Bottles of 56 tablets with child-resistant caps (NDC 64764-800-56)",
    "adverseReactions": "None."
}